| KODIAK SCIENCES DL-,0001 |
| USA |
| Gesundheit |
| US50015M1099 / A2N6P0 |
| K27 (Frankfurt) / KOD (NASDAQ) |
| FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD |
| - |
| https://kodiak.com/ |
|
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on o..
>Volltext.. |
| 1784.84 Mio. EUR |
| 1808.32 Mio. EUR |
| - |
| -193.86 Mio. EUR |
| -212.44 Mio. EUR |
| -3.68 EUR |
| 134.1 Mio. EUR |
| 110.52 Mio. EUR |
| -139.14 Mio. EUR |
| 2.39 |
| - |
| -24.91% |
| - |
| - |
| - |
| - |
| KODIAK SCIENCES |
| 28.09.26 |
|
||||
|
||||
|
||||
|